Correlation Between Acrivon Therapeutics, and Oncorus
Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and Oncorus at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and Oncorus into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Acrivon Therapeutics, Common and Oncorus, you can compare the effects of market volatilities on Acrivon Therapeutics, and Oncorus and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of Oncorus. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and Oncorus.
Diversification Opportunities for Acrivon Therapeutics, and Oncorus
0.48 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Acrivon and Oncorus is 0.48. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and Oncorus in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oncorus and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with Oncorus. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oncorus has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and Oncorus go up and down completely randomly.
Pair Corralation between Acrivon Therapeutics, and Oncorus
If you would invest 655.00 in Acrivon Therapeutics, Common on September 23, 2024 and sell it today you would earn a total of 16.00 from holding Acrivon Therapeutics, Common or generate 2.44% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 4.76% |
Values | Daily Returns |
Acrivon Therapeutics, Common vs. Oncorus
Performance |
Timeline |
Acrivon Therapeutics, |
Oncorus |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Acrivon Therapeutics, and Oncorus Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Acrivon Therapeutics, and Oncorus
The main advantage of trading using opposite Acrivon Therapeutics, and Oncorus positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, Oncorus can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncorus will offset losses from the drop in Oncorus' long position.Acrivon Therapeutics, vs. Fate Therapeutics | Acrivon Therapeutics, vs. Sana Biotechnology | Acrivon Therapeutics, vs. Caribou Biosciences | Acrivon Therapeutics, vs. Arcus Biosciences |
Oncorus vs. Apollomics Class A | Oncorus vs. Pyxis Oncology | Oncorus vs. Zura Bio Limited | Oncorus vs. Altamira Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Complementary Tools
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |